Selumetinib(AZD6244) 是一种选择性、非ATP竞争性口服MEK1/2抑制剂，对MEK1的IC50为14 nM，并抑制ERK1/2的磷酸化。

Trametinib (GSK1120212；JTP-74057) 是一种口服活性的 MEK 抑制剂，抑制 MEK1 和 MEK2 的 IC50 值约为 2 nM。Trametinib 激活自噬并诱导细胞凋亡。

U0126-EtOH（U0126）是一种高效、非ATP竞争性和选择性的MEK1和MEK2抑制剂，IC50值分别为72 nM和58 nM。它还抑制自噬和线粒体自噬。

CI-1040（PD 184352）是一种口服活性、高度特异性的小分子MEK抑制剂，对MEK1的IC50为17 nM。

PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM, specifically inhibits MEK-1-mediated activation of MAPK and does not directly inhibit ERK1 or ERK2.

TAK-733 is a potent and selective MEK allosteric site inhibitor for MEK1 with IC50 of 3.2 nM, inactive to Abl1, AKT3, c-RAF, CamK1, CDK2, c-Met, etc.

SL327 is a cell-permeable vinylogous cyanamide that acts as a selective inhibitor of MEK-1 and MEK-2 (IC50 = 0.18 and 0.22 μM respectively).

Refametinib（BAY 869766；RDEA119）是一种口服有效的高效非ATP竞争性选择性MEK1/MEK2抑制剂，对MEK1和MEK2的IC50值分别为19 nM和47 nM。

GDC-0623 is a selective and ATP-uncompetitive MEK1 inhibitor with Ki value of 0.13 nM.

BI-847325 is a selective and orally bioavailable dual MEK/Aurora kinase inhibitor with IC50 of 3 nM (Xenopus laevis Aurora B), 25 nM (human Aurora A), 15 nM (human Aurora C), 25 nM (human MEK1), and 4 nM (human MEK2) respectively.

Cobimetinib (GDC-0973，RG7420) 是一种强效、选择性、口服 MEK1 抑制剂，对 MEK1 的 IC50 为 4.2 nM。

Myricetin（标准品）作为Myricetin的分析标准，旨在用于研究和分析应用。这种植物衍生的黄酮类化合物表现出强效的抗氧化、抗癌、抗糖尿病和抗炎活性。